Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo

Xiaoxia Zhong, Erhu Zhao, Chunling Tang, Weibo Zhang, Juan Tan, Zhen Dong, Hanfei Ding, Hongjuan Cui

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

As the first member of glycylcycline bacteriostatic agents, tigecycline is approved as a novel expanded-spectrum antibiotic, which is clinically available. However, accumulating evidence indicated that tigecycline was provided with the potential application in cancer therapy. In this paper, tigecycline was shown to exert an anti-proliferative effect on neuroblastoma cell lines. Furthermore, it was found that tigecycline induced G1-phase cell cycle arrest instead of apoptosis by means of Akt pathway inhibition. In neuroblastoma cell lines, the Akt activator insulin-like growth factor-1 (hereafter referred to as IGF-1) reversed tigecycline-induced cell cycle arrest. Besides, tigecycline inhibited colony formation and suppressed neuroblastoma cells xenograft formation and growth. After tigecycline treatment in vivo, the Akt pathway inhibition was confirmed as well. Collectively, our data provided strong evidences that tigecycline inhibited neuroblastoma cells growth and proliferation through the Akt pathway inhibition in vitro and in vivo. In addition, these results were supported by previous studies concerning the application of tigecycline in human tumors treatment, suggesting that tigecycline might act as a potential candidate agent for neuroblastoma treatment.

Original languageEnglish (US)
Pages (from-to)7615-7623
Number of pages9
JournalTumor Biology
Volume37
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Neuroblastoma
Cell Proliferation
Anti-Bacterial Agents
Pharmaceutical Preparations
tigecycline
In Vitro Techniques
G1 Phase Cell Cycle Checkpoints
Cell Line
G1 Phase
Somatomedins
Growth
Cell Cycle Checkpoints
Insulin-Like Growth Factor I
Heterografts
Neoplasms
Apoptosis

Keywords

  • Akt activation
  • Cell cycle arrest
  • Cell proliferation
  • Neuroblastoma
  • Tigecycline

ASJC Scopus subject areas

  • Cancer Research

Cite this

Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo. / Zhong, Xiaoxia; Zhao, Erhu; Tang, Chunling; Zhang, Weibo; Tan, Juan; Dong, Zhen; Ding, Hanfei; Cui, Hongjuan.

In: Tumor Biology, Vol. 37, No. 6, 01.06.2016, p. 7615-7623.

Research output: Contribution to journalArticle

Zhong, Xiaoxia ; Zhao, Erhu ; Tang, Chunling ; Zhang, Weibo ; Tan, Juan ; Dong, Zhen ; Ding, Hanfei ; Cui, Hongjuan. / Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo. In: Tumor Biology. 2016 ; Vol. 37, No. 6. pp. 7615-7623.
@article{65b7920a69f443cca9f4c7f0a559d4d9,
title = "Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo",
abstract = "As the first member of glycylcycline bacteriostatic agents, tigecycline is approved as a novel expanded-spectrum antibiotic, which is clinically available. However, accumulating evidence indicated that tigecycline was provided with the potential application in cancer therapy. In this paper, tigecycline was shown to exert an anti-proliferative effect on neuroblastoma cell lines. Furthermore, it was found that tigecycline induced G1-phase cell cycle arrest instead of apoptosis by means of Akt pathway inhibition. In neuroblastoma cell lines, the Akt activator insulin-like growth factor-1 (hereafter referred to as IGF-1) reversed tigecycline-induced cell cycle arrest. Besides, tigecycline inhibited colony formation and suppressed neuroblastoma cells xenograft formation and growth. After tigecycline treatment in vivo, the Akt pathway inhibition was confirmed as well. Collectively, our data provided strong evidences that tigecycline inhibited neuroblastoma cells growth and proliferation through the Akt pathway inhibition in vitro and in vivo. In addition, these results were supported by previous studies concerning the application of tigecycline in human tumors treatment, suggesting that tigecycline might act as a potential candidate agent for neuroblastoma treatment.",
keywords = "Akt activation, Cell cycle arrest, Cell proliferation, Neuroblastoma, Tigecycline",
author = "Xiaoxia Zhong and Erhu Zhao and Chunling Tang and Weibo Zhang and Juan Tan and Zhen Dong and Hanfei Ding and Hongjuan Cui",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s13277-015-4613-6",
language = "English (US)",
volume = "37",
pages = "7615--7623",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo

AU - Zhong, Xiaoxia

AU - Zhao, Erhu

AU - Tang, Chunling

AU - Zhang, Weibo

AU - Tan, Juan

AU - Dong, Zhen

AU - Ding, Hanfei

AU - Cui, Hongjuan

PY - 2016/6/1

Y1 - 2016/6/1

N2 - As the first member of glycylcycline bacteriostatic agents, tigecycline is approved as a novel expanded-spectrum antibiotic, which is clinically available. However, accumulating evidence indicated that tigecycline was provided with the potential application in cancer therapy. In this paper, tigecycline was shown to exert an anti-proliferative effect on neuroblastoma cell lines. Furthermore, it was found that tigecycline induced G1-phase cell cycle arrest instead of apoptosis by means of Akt pathway inhibition. In neuroblastoma cell lines, the Akt activator insulin-like growth factor-1 (hereafter referred to as IGF-1) reversed tigecycline-induced cell cycle arrest. Besides, tigecycline inhibited colony formation and suppressed neuroblastoma cells xenograft formation and growth. After tigecycline treatment in vivo, the Akt pathway inhibition was confirmed as well. Collectively, our data provided strong evidences that tigecycline inhibited neuroblastoma cells growth and proliferation through the Akt pathway inhibition in vitro and in vivo. In addition, these results were supported by previous studies concerning the application of tigecycline in human tumors treatment, suggesting that tigecycline might act as a potential candidate agent for neuroblastoma treatment.

AB - As the first member of glycylcycline bacteriostatic agents, tigecycline is approved as a novel expanded-spectrum antibiotic, which is clinically available. However, accumulating evidence indicated that tigecycline was provided with the potential application in cancer therapy. In this paper, tigecycline was shown to exert an anti-proliferative effect on neuroblastoma cell lines. Furthermore, it was found that tigecycline induced G1-phase cell cycle arrest instead of apoptosis by means of Akt pathway inhibition. In neuroblastoma cell lines, the Akt activator insulin-like growth factor-1 (hereafter referred to as IGF-1) reversed tigecycline-induced cell cycle arrest. Besides, tigecycline inhibited colony formation and suppressed neuroblastoma cells xenograft formation and growth. After tigecycline treatment in vivo, the Akt pathway inhibition was confirmed as well. Collectively, our data provided strong evidences that tigecycline inhibited neuroblastoma cells growth and proliferation through the Akt pathway inhibition in vitro and in vivo. In addition, these results were supported by previous studies concerning the application of tigecycline in human tumors treatment, suggesting that tigecycline might act as a potential candidate agent for neuroblastoma treatment.

KW - Akt activation

KW - Cell cycle arrest

KW - Cell proliferation

KW - Neuroblastoma

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=84950265879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950265879&partnerID=8YFLogxK

U2 - 10.1007/s13277-015-4613-6

DO - 10.1007/s13277-015-4613-6

M3 - Article

C2 - 26687647

AN - SCOPUS:84950265879

VL - 37

SP - 7615

EP - 7623

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 6

ER -